Edition:
United States

People: Vanda Pharmaceuticals Inc (VNDA.O)

VNDA.O on Consolidated Issue listed on NASDAQ Global Market

15.60USD
2 Dec 2016
Change (% chg)

$0.10 (+0.65%)
Prev Close
$15.50
Open
$15.30
Day's High
$15.78
Day's Low
$15.20
Volume
383,594
Avg. Vol
782,304
52-wk High
$18.00
52-wk Low
$6.91

Kelly, James 

Mr. James Patrick Kelly is Chief Financial Officer, Senior Vice President, Treasurer, Secretary of Vanda Pharmaceuticals Inc., since December 13, 2010. Prior to joining Vanda, Mr. Kelly was Vice President and Controller at MedImmune, a biotechnology subsidiary of the AstraZeneca Group. Mr. Kelly joined MedImmune in 2006 as Director of Sales and Marketing Finance. From 2000 through 2005, Mr. Kelly was at Biogen Idec serving in research and development finance roles of increasing responsibility, most recently as the Director of Planning and Operations. From 1997 to 2000, Mr. Kelly was a member of the corporate finance team at Aetna Inc. which was responsible for mergers and acquisitions and treasury management. Mr. Kelly began his life sciences career in 1991 with Janssen Pharmaceuticals, a division of Johnson & Johnson. Mr. Kelly is a CFA charterholder and a member of the Association of Bioscience Financial Officers (“ABFO”).

Basic Compensation

Total Annual Compensation, USD 540,000
Restricted Stock Awards, USD 245,400
Long-Term Incentive Plans, USD --
All Other, USD 440,811
Fiscal Year Total, USD 1,226,210

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --